Compare ACGL & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGL | ILMN |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | Bermuda | United States |
| Employees | 8000 | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 26.7B |
| IPO Year | N/A | 2000 |
| Metric | ACGL | ILMN |
|---|---|---|
| Price | $99.18 | $189.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 17 |
| Target Price | $108.50 | ★ $124.24 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | N/A | $6.47 |
| Revenue Next Year | $3.34 | $5.58 |
| P/E Ratio | ★ $8.45 | $90.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $82.45 | $88.00 |
| 52 Week High | $107.09 | $207.00 |
| Indicator | ACGL | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 53.89 |
| Support Level | $96.38 | $117.64 |
| Resistance Level | $100.91 | $196.66 |
| Average True Range (ATR) | 2.36 | 7.81 |
| MACD | -0.61 | -0.66 |
| Stochastic Oscillator | 26.51 | 56.08 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.